chemotherapy-induced leukopenia of colorectal cancer
Conditions
Interventions
Observation group:Use Lulong Zaisheng Decoction II
Control group:Use simulants of Lulong Zaisheng Decoction II
Sponsors
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1) Patients who meet the above Western diagnostic criteria for stage II to IV colorectal cancer with reduced leukocyte I-II degree after primary treatment (adjuvant chemotherapy or first-line chemotherapy); (2) TCM clinical syndrome differentiation is Qi and blood deficiency syndrome; (3) The chemotherapy regimen used was CAPEOX; (4) Patients with stage IV recurrence and metastasis can be combined with bevacizumab or cetuximab targeted therapy according to gene detection; (5)18 years old = age <80 years old, gender unlimited, expected survival =3 months; (6) Quality of life score (Karnofsky score, KPS)=60 points; (7) Two consecutive cycles of chemotherapy could be completed after enrollment; (8) Good compliance, voluntary participation in this study, and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Those who do not meet the inclusion criteria; (2) Age <18 years old or =80 years old; (3) lactating and pregnant women; (4) leukopenia and/or platelets and/or hemoglobinia caused by non-chemotherapy factors; (5) Patients with primary blood system diseases and hematopoietic dysfunction; (6) Patients with severe heart, brain, liver, kidney and other primary diseases who cannot tolerate chemotherapy; (7) People who are allergic or allergic to the drugs in this study; (8) Mental or cognitive impairment, poor compliance, unable to cooperate with the researcher; (9) Participants in other clinical studies or taking other Chinese medicine, proprietary Chinese medicine or external treatment with Chinese medicine at the same time may affect the observers of the effect indicators of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral white blood cell count;the incidence of grade III to IV leukopenia; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of grade III to IV N, PLT and Hb in the two groups;Peripheral blood T lymphocyte subsets;Antibiotic use rate, chemotherapy completion rate;Changes of peripheral blood immune and intestinal microbiome before and after treatment;Changes of TCM clinical syndrome score; Quality of life efficacy evaluation criteria;Bone marrow hematopoietic function was evaluated by magnetic resonance imaging; | — |
Countries
China
Contacts
Public ContactFang Zhijun
Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Outcome results
None listed